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Abstract
Aplastic Anemia (AA) is a bone marrow failure (BMF) disorder, resulting in bone marrow hypocellularity and peripheral
pancytopenia. Severe aplastic anemia (SAA) is a subset of AA defined by a more severe phenotype. Although the
immunological nature of SAA pathogenesis is widely accepted, there is an increasing recognition of the role of
dysfunctional hematopoietic stem cells in the disease phenotype. While pediatric SAA can be attributable to genetic
causes, evidence is evolving on previously unrecognized genetic etiologies in a proportion of adults with SAA. Thus,
there is an urgent need to better understand the pathophysiology of SAA, which will help to inform the course of
disease progression and treatment options. We have derived induced pluripotent stem cell (iPSC) from three
unaffected controls and three SAA patients and have shown that this in vitro model mimics two key features of the
disease: (1) the failure to maintain telomere length during the reprogramming process and hematopoietic
differentiation resulting in SAA-iPSC and iPSC-derived-hematopoietic progenitors with shorter telomeres than controls;
(2) the impaired ability of SAA-iPSC-derived hematopoietic progenitors to give rise to erythroid and myeloid cells.
While apoptosis and DNA damage response to replicative stress is similar between the control and SAA-iPSC-derived-
hematopoietic progenitors, the latter show impaired proliferation which was not restored by eltrombopag, a drug
which has been shown to restore hematopoiesis in SAA patients. Together, our data highlight the utility of patient
specific iPSC in providing a disease model for SAA and predicting patient responses to various treatment modalities.
Introduction
Aplastic Anemia (AA) is a rare and serious bone mar-
row disorder associated with hypocellular bone marrow
and peripheral pancytopenia. Severe AA (SAA) is a sub-
type of the disease characterized by very low bone marrow
cellularity of less than 25%, with significant morbidity and
mortality1. AA occurs with peak incidences at the two
extremes of life, in patients between the age of 10 and 25,
and patients aged>60 years. Children with AA are more
often treated with hematopoietic stem cell transplantation
(HSCT) while adults are treated with either immuno-
suppressive therapy using anti-thymocyte globulin (ATG)
and Cyclosporine or HSCT, if a matched donor is avail-
able2. Currently, 70–80% of cases are classified as idio-
pathic because their etiology is unknown. The remainder
(15–20%) consists of constitutional bone marrow failure
syndromes with the most common being Fanconi anemia
(FA) followed by the telomeropathies such as dyskeratosis
congenital (DC).
There are currently two proposed models of pathogen-
esis in idiopathic AA that could explain the characteristic
marrow hypocellularity observed in this disorder. In model
1, an underlying abnormality of the hematopoietic stem
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cells (HSCs) may result in a predisposition to stem cell
damage, as well as qualitative or quantitative defects of
HSC production. In model 2, a deregulated immune
response targets a normal HSC compartment. Strong
evidence for an immune component to the pathogenesis of
AA comes from the success of the immunosuppressive
therapies in treating AA and associated clinical features,
including aberrations in immune cell number, phenotype
and function2. Evidence for an underlying stem cell/pro-
genitor defect is derived from the observations of reduced
hematopoietic progenitor cell numbers both at presenta-
tion and following successful therapy with ATG3,4,
enhanced apoptosis of HSCs, upregulation of genes
involved in cell death in hematopoietic progenitors
obtained from AA patients5–7 and mutations in genes such
as PRF18, MPL9, NSB110, SBSD11, TERT, TERC, and
TIF212 as well as polymorphisms in the IFN gamma13
found in a small number of patients.
Acquisition of cells from the bone marrow of AA
patients is complicated by the paucity of hematopoietic
stem/progenitor cells in these patients and the lack of
mouse models which recapitulate the entire spectrum of
AA14–16. Here we describe the generation of an iPSC-
derived disease model for SAA consisting of iPSC lines
derived from 1 pediatric and 2 young adult cases and 3
unaffected controls. These iPSC lines were differentiated
to hematopoietic lineages and although no significant
differences were observed in the ability to give rise to
hematopoietic progenitors between control and SAA-
iPSC, the later, showed a reduced potential to generate
erythroid and myeloid cells, impaired proliferation and
shorter telomeres when compared to unaffected controls.
Results
Generation of human iPSC from control and SAA patient
fibroblasts
To generate an in vitro disease model for SAA, dermal
fibroblasts cells from 1 pediatric and 2 young adult cases
of idiopathic SAA, showing severe and very severe clinical
manifestation and no clinical stigmata of constitutional
AA as well as three unaffected controls (indicated as WT
throughout the manuscript) were transduced with the
non-integrating RNA-derived Sendai virus (SeV) vector
including the four Yamanaka reprogramming factors
(OCT4, SOX2, KLF4, c-MYC) as previously reported17
(Table 1). SAA fibroblasts showed slightly reduced
reprogramming efficiencies compared to unaffected con-
trols (Table 1). No residual presence of the SeV trans-
genes was detected in any of the lines generated indicating
that SAA-iPSC and control lines successfully maintained
stable regulation of the endogenous pluripotent gene
expression activated during reprogramming after the loss
of SeV transgene expression (Supplementary Fig. 1).
Cytogenetic analysis carried out by single nucleotide
polymorphisms (SNP) array showed that the reprogram-
ming process/prolonged culture of the iPSC lines did not
induce any detectable genomic abnormalities with the
exception of SAA1-iPSC in which two loss of hetero-
zygosity events were identified (Supplementary Table 1).
SAA-iPSC colonies displayed characteristic human ESC-
like morphology and expression of pluripotent markers
(Fig. 1a, Supplementary Fig. 2a and b). Similarly, in vivo
assessment of pluripotency revealed that SAA-iPSC lines
induced formation of teratomae containing cells belong-
ing to all three germ layers (Fig. 1b, Supplementary
Fig. 2c). These data indicate that SAA-iPSC and control-
iPSC lines displayed characteristic features of fully-
reprogrammed cells.
Reduced colony-forming potential of SAA iPSC-derived
hematopoietic progenitors
To investigate the hematopoietic differentiation poten-
tial of the SAA-iPSC lines, all patient specific and control
iPSC were differentiated using a method previously
described by Olivier et al.18. Early stages of mesoderm
induction from iPSC cultures were monitored on day 3 of
Table 1 Table providing detailed information regarding SAA patients used in this study and reprogramming efficiencies
obtained for each control and patient
Patient ID Age (years) Gender Phenotype Reprogramming efficiency
WT1 Newborn Male Heathy 0.21%
WT2 51 Male Healthy 0.29%
WT3 37 Female Healthy 0.14%
SAA1 16 Male Severe AA Responded to immunosuppressors 0.11%
SAA2 24 Male Very Severe AA Responded to immunosuppressors Developed PNH and
relapsed Failed with second course of horse ATG Successful matched
unrelated HSCT
0.10%
SAA3 10 Female Very Severe AA and autism Successful matched unrelated HSCT 0.11%
AA aplstic anemia, PNH paroxysmal nocturnal hemaoglobinuria, ATG anti-thymocyte globulin, HSCT hematopoietic stem cell transplantation
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differentiation by expression of KDR (FLK1)19. Genera-
tion of the first hematopoietic progenitors was detected at
day 6 using the CD43 pan-hematopoietic marker20,21. The
emergence of hematopoietic progenitors (CD43+) and
the subtypes of hematopoietic progenitors including
megakaryocyte progenitors (CD41a+CD235a−), ery-
throid progenitors (CD41a-CD235a+), megakaryocyte/
erythroid progenitors (CD41a+CD235a+) and myeloid
progenitors (CD41a-CD235a−) was assessed by flow
cytometric analysis throughout the differentiation time
course20 (Fig. 2a). To identify the sources of variation that
could affect the ability to generate hematopoietic pro-
genitors, different variables such as differentiation
experiment, passage number, clonal and donor cell origin
(genetic background) were compared using the control-
iPSC lines by flow cytometric analysis22 (Supplementary
Fig. 3a). None of these parameters showed a statistically
significant difference in the percentage of CD43 positive
cells at day 12 (Supplementary Fig. 3b–d). Hence, one
clone from each patient and control was used throughout
this study. To enable comparison of data from each
patient against all three controls, the latter were pooled
together, averaged and shown as WT throughout the
manuscript.
Analysis of mesodermal induction in SAA-iPSC lines at
day 3 revealed that patient cell lines showed similar fre-
quencies of KDR+ compared to control-iPSC lines
(Fig. 2b). No significant reduction in the potential to
generate CD43+ hematopoietic progenitors was observed
in any of the SAA-iPSC cell lines compared to unaffected
controls at days 6 and 12 (Figs. 2c and 3b); however one of
the SAA patient iPSC (SAA1) showed a statistically sig-
nificant reduction in the potential to generate erythroid
progenitors (CD43+CD41a−CD235a+) (Fig. 3b).
To assess the colony-forming potential of the SAA-iPSC
cell lines, we performed colony forming unit (CFU) assay
at day 12 by culturing iPSC-derived-hematopoietic pro-
genitors in methylcellulose-derived media enriched with
recombinant cytokines which promote the differentiation
into committed erythroid progenitors (CFU-E and BFU-
E), and myeloid lineage progenitors (CFU-G, CFU-M,
CFU-GM, and CFU-GEMM) (Fig. 2a). All three SAA-
iPSC-derived hematopoietic progenitors showed a sig-
nificant reduction in the total number of CFUs indicating
Fig. 1 SAA-iPSC lines display in vitro hallmarks of pluripotency. a Brightfield images of control and SAA-iPSC colonies displaying typical ESC-like
morphology and staining of control and SAA-iPSC colonies with pluripotency markers. DAPI staining is shown in blue. Scale bars, 100 µm;
b Histological analysis of representative teratomae generated for control and SAA-iPSC lines displaying trilineage differentiation. Scale bars, overall
500 µm, ectoderm 100 µm, mesoderm 200 µm, ectoderm 100 µm
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Fig. 2 SAA-iPSC differentiation into mesodermal and hematopoietic progenitors. a Schematic representation of the experimental design used
to analyze the WT and SAA-iPSC hematopoietic differentiation capacity; b Representative images of flow cytometric analysis and scatter dot plot
representation of KDR expression in WT and SAA cell lines on day 3. c Representative images of flow cytometric analysis and scatter dot plot
representation of CD43 expression in differentiating WT and SAA cell lines on day 6. b One-way ANOVA with Dunnett’s multiple comparison test was
used for statistical comparison between WT and SAA cell lines. c Kruskal-Wallis with Dunn’s multiple comparison test was used for statistical
comparison between WT and SAA cell lines. b, c Data is presented as mean of at least 3 independent experiments ± S.E.M. Data for all control cell
lines is averaged in one group (WT)
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Fig. 3 SAA-iPSC-derived-hematopoietic progenitors show a reduced colony-forming potential. a Representative images of flow cytometric
analysis of CD34 and CD43 expression and CD41 and CD235 expression on CD43+ population in WT and SAA cell lines on day 12 of differentiation;
b Analysis of percentages of hematopoietic progenitors (CD43+), erythroid progenitors (CD43+CD41a−CD235a+) and myeloid progenitors (CD43+CD41a
−CD235a-) in WT and SAA cell lines on day 12. Kruskal-Wallis with Dunn’s multiple comparison test was used for hematopoietic progenitors and one-way
ANOVA with Dunnett’s multiple comparison test was used for erythroid and myeloid progenitors for statistical comparison between WT and SAA cell lines
in; c Analysis of total colony-forming units (CFUs), erythroid-lineage CFUs and myeloid-lineage CFUs generated from WT and SAA-iPSC based
hematopoietic progenitors on day 12. One-way ANOVA with Dunnett’s multiple comparison test was used for statistical comparison between WT and SAA
cell lines; b, c data is presented as mean of at least three independent experiments ± S.E.M. Data for all control cell lines is averaged in one group (WT)
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an impaired hematopoietic colony-forming capacity,
including both erythroid and myeloid colony potential
(Fig. 3c). Despite reduced hematopoietic colony number
in SAA, no differences in types and ratios of colonies
formed were observed (data not shown). Similar data were
obtained at day 16 of differentiation (Supplementary
Fig. 4), suggesting that the impaired hematopoietic colony
forming ability was not due to a delay in differentiation
process.
Telomerase-independent impaired telomere elongation in
SAA-iPSC cell lines and enhanced telomere attrition during
hematopoietic differentiation
Excessive telomere attrition in highly proliferative cells
such as hematopoietic stem and progenitor cells can lead
to bone marrow failure23. Although the SAA patients used
in this study did not display typical dyskeratosis congenita
phenotype or mutations in DKC1, TINF2, TERT or TERC
genes by exome sequencing analysis (Supplementary
Tables 2 and 3), we decided to investigate the telomere
dynamics in our SAA-iPSC model since it has been
reported that one third of acquired AA patients present
short telomeres in leukocytes24–26. Control-iPSC showed
longer telomeres than parental fibroblasts due to telomere
elongation during reprogramming, corroborating pub-
lished reports27. No increases in telomere length were
observed during the reprogramming of SAA fibroblasts
(Fig. 4a). Furthermore, one of the patients (SAA3) showed
continued telomere shortening during the reprogram-
ming process (Fig. 4a), resulting in iPSC with telomeres
Fig. 4 SAA-iPSC exhibit deficient telomere elongation during reprogramming and telomere shortening upon hematopoietic
differentiation. a Analysis of telomere length in parental fibroblasts (dark grey bars) and iPSC passage 30 (light blue bars) and 50 (green bars) in WT
controls and SAA cell lines. One-way ANOVA with Tukey’s multiple comparison test was used for statistical comparison between fibroblasts and iPSC
passage 30 and passage 50 (*p < 0.05); b Analysis of telomere length in iPSC passage 50 (green bars) and iPSC-based hematopoietic progenitors
(HPC) differentiated from iPSC passage 50 (light grey bars) in WT controls and SAA cell lines. Multiple t-test using Holm-Sidak method was used for
statistical comparison between iPSC passage 50 and HPC; c Analysis of telomerase activity in parental fibroblasts (dark grey bars) and iPSC at passage
30 (light blue bars) and 50 (green bars) in WT controls and SAA cell lines. One-way ANOVA with Tukey’s multiple comparison test was used for
statistical comparison between fibroblasts and iPSC passage 30 and passage 50; d Analysis of telomerase activity in iPSC passage 50 (green bars) and
iPSC-based hematopoietic progenitors (HPC) differentiated from iPSC passage 50 (light grey bars) in WT and SAA cell lines. Multiple t-test using
Holm–Sidak method was used for statistical comparison between iPSC passage 50 and HPC. a–d data is presented as mean of at least 3 independent
experiments ± S.E.M. Data for all control cell lines is averaged in one group (WT)
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which were significantly shorter than parent fibroblasts.
The control iPSC lines did not show a significant telomere
shortening during the 12 day differentiation time course
to hematopoietic lineages; however all SAA-iPSC lines
displayed a significant telomere attrition during the dif-
ferentiation process, resulting in iPSC-derived-
hematopoietic progenitors with significantly shorter tel-
omeres than undifferentiated iPSC (Fig. 4b),corroborating
data obtained with AA patient specific peripheral blood
and bone marrow nucleated cells26,28–30.
We assessed telomerase activity in iPSC and iPSC-
derived-hematopoietic progenitors by telomere repeat
amplification analysis. Telomerase activity was sig-
nificantly increased in iPSC when compared to parental
fibroblasts indicating the expected up-regulation of telo-
merase activity during reprogramming of both control
and SAA fibroblasts as reported from other studies31
(Fig. 4c). Likewise, analysis of telomerase activity in iPSC-
derived-hematopoietic progenitors revealed no significant
differences in telomerase activity compared to undiffer-
entiated iPSC (Fig. 4d). Together, these data indicate
impaired telomere elongation during the reprogramming
of SAA fibroblasts, independent of telomerase activity
measured by in vitro assays.
Reduced proliferation capacity of SAA-iPSC-derived
hematopoietic progenitors
Progressive telomere shortening leads eventually to cell
cycle arrest or cell death32,33. In view of this as well as the
reduced capacity of SAA-iPSC to give rise to erythroid
and myeloid cells, we investigated the proliferative
capacity and apoptosis of the SAA iPSC-derived-
hematopoietic progenitors. We synchronized the iPSC-
derived-hematopoietic progenitors in G1/S phase by
treatment with ribonucleotide reductase inhibitor hydro-
xyurea (HU) for 24 h. This was followed by culture in HU-
free media and pulsing with 5-bromo-2-deoxyuridine
(BrdU) for 1 h (Fig. 5a). Flow cytometric analysis of DNA
content and incorporation of BrdU in control-iPSC-
derived-hematopoietic progenitors indicated a high per-
centage of cells arrested in G1/S phase at 1 and 3 h post-
release from HU due to depletion of deoxyribonucleotide
pools (Supplementary Fig. 5a). These arrested cells reen-
tered the cell cycle, progressed through S-phase and
showed a similar cell cycle profile to that of untreated
cells at 24 h post treatment (Supplementary Fig. 5a, b),
indicating that iPSC-derived-hematopoietic progenitors
require at least 24 h to restore a normal cell-cycle profile.
We analyzed the proliferation rate of the synchronized
control and SAA-iPSC-derived-hematopoietic progeni-
tors (marked by CD43 expression) by comparing the
percentage of BrdU-incorporating cells (S-phase) at 24 h
post-release from HU. Interestingly, SAA-iPSC-derived-
hematopoietic progenitors showed a significant reduction
in the number of BrdU-incorporating cells (proliferative
cells) compared with control counterparts, indicating a
reduced proliferative capacity (Fig. 5b). To investigate
whether apoptosis was increased in SAA-iPSC-derived-
hematopoietic progenitors, we measured the presence of
cleaved Poly (ADP-ribose) polymerase-1 (PARP) by flow
cytometric analysis. Cleaved-PARP analysis of early
apoptotic cells revealed a significant increase in the
apoptosis of SAA-iPSC-derived-hematopoietic progeni-
tors derived from one of the patients (SAA2) when
compared to control cells (Supplementary Fig. 5c).
However, no significant differences in apoptosis were
observed between patients and controls after HU treat-
ment (Supplementary Fig. 5d).
Induction of replicative stress by depletion of deoxyr-
ibonucleotide pools with long exposure to hydroxyurea
leads to stalled replication forks and accumulation of
DNA damage34. To address whether reduced hemato-
poietic potential of SAA-iPSC-derived-hematopoietic
progenitors might be attributed to an impaired ability to
repair DNA damage associated with replicative stress, we
analyzed the percentage of DNA damage induced by HU
treatment by flow cytometric analysis in proliferating and
non-proliferating cells (Fig. 5c–f). To assess the reversi-
bility of the DNA damage induced by HU exposure, we
measured the formation of the phosphorylated histone
variant H2AX (γH2AX) at 1, 3, 8, and 24 h after HU
release in control-iPSC-derived-hematopoietic progeni-
tors. This analysis indicated accumulation of γH2AX+ in
BrdU+ cells at 1 and 3 h after HU release indicating
accumulation of DNA damage in replication forks after
HU replication block (Supplementary Fig. 5e). The
γH2AX foci progressively disappeared showing similar
levels of γH2AX levels to those of untreated cells at 24 h
(Supplementary Fig. 5e). Thus, analysis of accumulation
of DNA damage in proliferating (γH2AX+BrdU+) and
non-proliferating (γH2AX+BrdU−) iPSC-derived-
hematopoietic progenitors showed that control cell lines
were able to repair the induced DNA damage after 24 h
release from HU (Supplementary Fig. 5f, g).
To investigate the ability of SAA cell lines to repair
DNA damage associated to replicative stress, we then
analyzed the accumulation of γH2AX in proliferating
(BrdU+) and non-proliferating (BrdU−) in SAA-iPSC-
derived-hematopoietic progenitors at 1 and 24 h after HU
release (Fig. 5c–f). No significant increase in the accu-
mulation of γH2AX+BrdU+ was observed at 1 h post HU
release in SAA-iPSC-derived hematopoietic progenitors
(Fig. 5c), unlike the control counterparts which showed a
significant accumulation of DNA damage at 1 h post HU
release. Low levels of DNA damage observed in BrdU+
after replicative stress points to a reduced proliferation
capacity likely due to a reduced formation of replication
forks, in agreement with our results showing significantly
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Fig. 5 (See legend on next page.)
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reduced number of BrdU-incorporating cells (Fig. 5b).
Thus, higher levels of γH2AX+BrdU+ cells were
observed in control-iPSC-derived-hematopoietic pro-
genitors compared to those in SAA cell lines, likely due to
a higher number of replication forks, although the dif-
ferences were not statistically significant (Fig. 5d). Inter-
estingly, analysis of DNA damage in in non-proliferating
(BrdU−) progenitors revealed a significant increase in the
level of γH2AX at 24 h post HU release in one of patient-
derived-hematopoietic progenitors (SAA2) compared to
equivalent cells generated from the controls (Fig. 5e),
suggesting an individual patient specific impaired ability
to restore normal levels of DNA damage after HU treat-
ment in non-proliferating iPSC-derived-hematopoietic
progenitors. Notwithstanding this, the percentage of
γH2AX+BrdU-cells in the hematopoietic progenitors
derived from this patient iPSC line was not significantly
higher when compared to equivalent cells generated
from the unaffected controls (Fig. 5f). Together these
data indicate that proliferating SAA-iPSC-derived-
hematopoietic progenitors tend to accumulate less DNA
damage soon after HU treatment most likely as result of
their reduced proliferation. Furthermore, a subset of
SAA-iPSC-derived-hematopoietic progenitors may be
slower or have an impaired ability to restore DNA damage
in the non-proliferative compartment. However, the
overall level of DNA damage induced in response to
replicative stress is not significantly different compared to
control-derived-hematopoietic progenitors, excluding
DNA damage accumulation as a key factor underlying
the impaired hematopoietic differentiation of SAA-iPSC
lines.
Eltrombopag does not improve hematopoietic
differentiation potential or enhance proliferation of
SAA-iPSC-derived-hematopoietic progenitors
Eltrombopag (EP) is a thrombopoietin (TPO) receptor
agonist that promotes megakaryocyte maturation and
platelet production without competing with endogenous
TPO35. Beyond its role in megakaryopoiesis and platelet
generation, TPO signaling has been also shown to be
critical for HSC homeostasis and expansion in animal
models and refractory SAA patients36–38. In view of these
findings, we investigated whether the observed reduced
colony-forming potential and proliferation of SAA-iPSC-
derived-hematopoietic progenitors could be rescued by
the addition of EP (10 µM) to the differentiation media
(Fig. 6a). Addition of EP to TPO containing differentiation
media induced a significant increase in the percentage of
erythroid progenitors (CD43+CD235a+CD41a−) at the
expense of megakaryocytic progenitors (CD43+CD235a-
CD41+) compared to the control group containing only
TPO in differentiation media (data not shown). These
results are very similar to what has been reported in CD34
+ bone marrow cells39 and indicate that EP is biologically
active in our iPSC differentiation system.
To assess EP’s impact on SAA-iPSC differentiation, we
added EP from day 6 of differentiation (Fig. 6a) in the
presence and absence of HU and performed CFU assays at
day 14 of differentiation. CFU assay results did not show
significant differences between DMSO and EP-treated
groups in the total number of colonies generated from
SAA-iPSC-derived-hematopoietic progenitors cultured in
absence of HU (Fig. 6b). Similarly, no differences were
observed when EP was added in parallel to replicative
stress inducing agent, HU (Fig. 6c).
EP favors the proliferation and DNA double-strand
break repair after γ-irradiation in human hematopoietic
stem and progenitor cells40,41. To investigate whether EP
is affecting the proliferative and DNA damage repair
capacity of the SAA-iPSC-derived-hematopoietic pro-
genitors under conditions of replicative stress induced by
HU, flow cytometric analysis for BrdU incorporation and
accumulation of γH2AX was carried out after EP treat-
ment. No significant differences were observed in the
percentage of BrdU+ cells, indicating that EP does not
affect the proliferation of control or SAA-iPSC-derived
(see figure on previous page)
Fig. 5 SAA-iPSC-derived-hematopoietic progenitors show a reduced proliferation capacity. a Schematic of the experimental design used to
analyze the proliferation, DNA repair capacity and apoptosis in SAA-iPSC-derived-hematopoietic progenitors; b Analysis of BrdU-incorporating cells in
WT and SAA iPSC-derived-hematopoietic progenitors. One-way ANOVA with Dunnett’s multiple comparison test was used for statistical comparison
between WT and SAA cell lines; c Analysis of γH2AX in BrdU+ cells in untreated (dark blue bars), 1 h after HU recovery (beige bars) and 24 h after HU
recovery (red bars) iPSC-derived-hematopoietic progenitors. One-way ANOVA with Tukey’s multiple comparison test was used for statistical
comparison between untreated cells and 1 h after HU recovery and 24 h after recovery; d Analysis of γH2AX in BrdU+ cells in WT and SAA iPSC-
derived-hematopoietic progenitors. One-way ANOVA with Dunnett’s multiple comparison test was used for statistical comparison between WT and
SAA cell lines; e Analysis of γH2AX in BrdU- cells in untreated (dark blue bars), 1 h after HU recovery (beige bars) and 24 h after HU recovery (red bars)
iPSC-derived-hematopoietic progenitors. One-way ANOVA with Tukey’s multiple comparison test was used for statistical comparison between
untreated cells and 1 h after HU recovery and 24 h after recovery,(*p < 0.05); f Analysis of γH2AX in BrdU- cells in WT and SAA iPSC-derived-
hematopoietic progenitors. One-way ANOVA with Dunnett’s multiple comparison test was used for statistical comparison between WT and SAA cell
lines. b–f data is presented as mean of at least 3 independent experiments ± S.E.M. Data for all control cell lines is averaged in one group (WT)
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hematopoietic progenitors (Fig. 7a). Similarly, no sig-
nificant changes were observed in the percentage of
proliferating and non-proliferating control-and SAA-
iPSC-derived-hematopoietic progenitors with γH2AX
foci (Fig. 7b, c). Together these data indicate that EP does
not affect the proliferative capacity, DNA repair ability
and colony forming potential of SAA-iPSC-derived-
hematopoietic progenitor cells.
Discussion
Studies of hematopoietic progenitor cell dysfunction in
SAA have been difficult due to paucity of these cells in
patient’s bone marrow samples. We have overcome this
difficulty by using an iPSC disease model of three patients
with SAA which has enabled us to study the phenotype of
hematopoietic progenitors independent of the influence
of the immune system.
SAA-iPSC lines were largely not impaired in their ability
to generate hematopoietic progenitors; however the latter
exhibited a much reduced erythroid and myeloid CFU
ability accurately recapitulating the phenotype that
defines SAA. The presence of reduced number and clo-
nogenic capacity of bone marrow hematopoietic pro-
genitors in AA patients has been reported by different
studies4,42,43 and traditionally considered secondary to
immune-mediated stem cell destruction24. Using our
in vitro SAA iPSC model, we provide evidence for an
impaired differentiation capacity in SAA hematopoietic
progenitors in the absence of an immune system, which
may be suggestive of a constitutional progenitor cell
dysfunction. Genetic background has been reported as
one of the major drivers of phenotypic variability in iPSC
modeling44–48. We minimized this effect in the SAA-iPSC
model by including multiple control cell lines in order to
Fig. 6 Eltrombopag does not improve the colony-forming potential of SAA-iPSC-derived-hematopoietic progenitors. a Schematic of the
experimental design used to analyze the effect of eltrombopag on the colony-forming potential, proliferation and DNA repair capacity in SAA-iPSC
based hematopoietic progenitors; b–d Analysis of CFUs generated in DMSO (dark blue bars) and eltrombopag-treated (orange bars) iPSC-derived-
hematopoietic progenitors in WT and SAA cell lines in non-replicative stress conditions; b Total CFUs, c erythroid-lineage CFUs, d myeloid-lineage
CFUs. e–g Analysis of CFUs generated in DMSO (red bars) and eltrombopag-treated (grey bars) iPSC-derived-hematopoietic progenitors in WT and
SAA cell lines under replicative stress conditions: e Total CFUs, f erythroid-lineage CFUs, gmyeloid-lineage CFUs. b–g Multiple t-test using Holm-Sidak
method was used for statistical comparison between DMSO and eltrombopag groups. Data is presented as mean of at least 3 independent
experiments ± S.E.M. Data for all control cell lines is averaged in one group (WT)
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distinguish between phenotypic effects caused by disease-
causing alterations and genetic background. Further
experiments using a larger number of iPSC lines from
relatives sharing similar genetic background are needed to
fully understand the disease pathogenesis.
Functional reconstruction of telomeres and upregula-
tion of telomerase activity during reprogramming repre-
sent a hallmark of induced pluripotency27,31,49. iPSC-
derived modeling of telomeropathies associated with
BMFs caused by mutations in telomerase-associated
genes such as TERC, TERT, and DKC have shown
defective telomere elongation in iPSC due to reduced
telomerase function which impacts on the maintenance of
pluripotent phenotype and hematopoietic differentiation
capacity50–52. In SAA, only 10% of patients with short
telomeres display known mutations in telomere pathway
components suggesting that mutations in uncharacterized
genes might have a role in the disease phenotype observed
in these patients24. Our results revealed that SAA fibro-
blasts failed to elongate telomeres during the repro-
gramming process despite up-regulation of telomerase
activity, pointing to an impaired telomere elongation
during the reprogramming process that is not attributable
to a defective telomerase activity. Similarly, iPSC-based
hematopoietic progenitors in SAA cell lines showed
excessive telomere shortening during hematopoietic dif-
ferentiation. It is possible that the presence of short tel-
omeres may be responsible for the impaired
hematopoietic differentiation capacity we observed in our
iPSC derived modeling of SAA51. Alternatively, the short
telomeres can be a consequence of reiterative rounds of
divisions carried out by a smaller number of proliferating
hematopoietic progenitor cells in SAA patients as a
compensatory mechanism to maintain homeostasis15. To
be able to distinguish between these possibilities and
investigate whether genetic predispositions play a role,
whole genome analysis of a large number of SAA patients
and their families need to be carried out. Our study
included three patients only which precludes such large
scale analysis, however exome sequencing analysis of
patient’s dermal fibroblasts revealed the presence of
deleterious mutations in telomere-associated genes such
as RPA2, NCL, POLD3, TEP1, YLMP1, PIF1, and ERCC4
(Supplementary Table 3). Interestingly, replication Pro-
tein A (RPA) has been reported to be necessary for telo-
mere maintenance due to its role in unfolding of
Fig. 7 Eltrombopag does not increase the proliferation capacity of SAA-iPSC-derived-hematopoietic progenitors. a. Analysis of BrdU-
incorporating cells in DMSO (red bars) and eltrombopag-treated (grey bars) iPSC-derived-hematopoietic progenitors in WT and SAA cell lines; b
Analysis of γH2AX in BrdU+ cells in DMSO (red bars) and eltrombopag-treated (grey bars) iPSC-derived-hematopoietic progenitors in WT and SAA cell
lines; c Analysis of γH2AX in BrdU-cells in DMSO (red bars) and eltrombopag-treated (grey bars) in iPSC-derived-hematopoietic progenitors in WT and
SAA cell lines. a–c Multiple t-test using Holm-Sidak method was used for statistical comparison between DMSO and eltrombopag groups. Data is
presented as mean of at least 3 independent experiments ± S.E.M. Data for all control cell lines is averaged in one group (WT)
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telomeric G-quadruplexes and preventing replication-fork
stalling53 whereas NCL codifies for the RNA chaperone
nucleolin that regulates the nuclear localization of telo-
merase54. Likewise, overexpression of Ylpm1 in mouse
embryonic stem cells leads to down-regulation of telo-
merase activity and telomere shortening resulting in
reduced proliferation and hematopoietic differentiation
ability55. Whilst these data point to existence of poten-
tially deleterious mutations in telomere-associated genes
in SAA patients, access to DNA samples from their
related family members and larger cohorts of SAA
patients is needed to confirm their involvement in SAA
etiology.
EP is a non-peptide molecule mimetic to TPO that sti-
mulates tri-lineage hematopoiesis in 40% of the SAA
patients at 3–4 months38,56. However, the mechanism by
which EP is promoting the generation of blood cells and
impacting hematopoietic stem and progenitors in AA
patients is not fully understood. We studied the ability of
EP to rescue the impaired hematopoietic differentiation
capacity in our SAA-iPSC model. SAA-iPSC-derived
hematopoietic progenitors did not show a significant
increase in the number of erythroid or myeloid-lineage
CFUs, proliferative capacity or DNA damage repair capa-
city under conditions of replicative stress, upon adding EP
during the differentiation process. Interestingly, it has been
reported that EP failed to improve severe thrombocytope-
nia in patients with constitutional bone marrow failures
syndromes including DC and Diamond-Blackfan-anemia57.
Thus, this lack of response to EP by DC patients supports
our hypothesis that constitutional defects in the telomere-
associated genes may be at the root of the impaired
hematopoietic differentiation observed in the SAA-iPSC-
derived hematopoietic progenitors. As such it would be of
interest to investigate if this group of patients will respond
to other available therapies, for example danazol, although
to date is unclear whether danazol related improvements
are due to upregulation of telomerase activity through an
increase in TERT expression or to elongation of telo-
meres58,59. Likewise, different authors have hypothesized
that EP might be involved in immune cell function by
modulating regulatory T cell function in SAA patients38,60
as observed in chronic idiopathic thrombocytopenic pur-
pura patients treated with EP61. The lack of response to EP
observed in our SAA-iPSC model suggests that EP may
indeed have an underlying immune-regulatory function,
which is separate to the impaired differentiation and telo-
mere maintenance defect reported herein. In summary, our
data provide strong evidence for usefulness of iPSC based
disease modeling to replicate key phenotypes associated
with SAA, facilitating the diagnosis of previously uni-
dentified cases of constitutional SAA, and predicting
patient specific response to various treatment modalities.
Material and methods
Generation of iPSC lines from SAA patients and healthy
volunteers
Human fibroblasts from three healthy volunteers, one
neonatal (Lonza, CC-2509) and two adult (Lonza, CC-
2511), and three patients with pediatric SAA were cultured
with Advanced Dulbecco’s Modified Eagle Medium
(Thermo-Fisher, Waltham, MA, USA) containing 10% FBS
(Thermo Fisher Scientific), 1% Glutamax (Thermo Fisher
Scientific) and 1% penicillin/streptomycin (Thermo Fisher
Scientific) at 37 °C and 5% CO2 in a humidified incubator.
Fibroblasts were transduced using the CytotuneTM-iPS
Reprogramming Kit (Thermo Fisher Scientific, A13780-
01) according to manufacturer’s instructions. iPSC colo-
nies were established on inactivated primary mouse
embryonic fibroblasts feeder layer and then adapted to a
feeder-free system, cultured on recombinant Vitronectin
(Thermo Fisher Scientific) and in StemPro hESC SFM®
media (Thermo Fisher Scientific) supplemented with 8ng/
ml basic Fibroblast Growth Factor (Thermo Fisher Sci-
entific), 1% penicillin/streptomycin and 0.1mM 2-
mercaptoethanol (Thermo Fisher Scientific).
In vitro test of pluripotency
For immunocytochemistry analysis, iPSC colonies were
fixed in 4% Formaldehyde (Sigma-Aldrich) and permea-
bilised with 0.25% Triton-X-100 (Sigma-Aldrich). Fol-
lowing treatment, cells were stained with mouse anti-
human SSEA4-Alexa Fluor® 555 (Beckton Dickinson, BD;
Franklin Lakes, NJ, USA, 560218) at 1:60 dilution, mouse
anti-human TRA-1-60-FITC (Merck Millipore, Billerica,
MA, USA, FCMAB115F) at 1:60 dilution, mouse anti-
NANOG-AF647 (Cell Signaling Technologies, Danvers,
MA, USA, 5448) at 1:150 dilution and goat antihuman
OCT4 primary antibody (R&D, Minneapolis, MN, USA,
AF1759) at 1:60 dilution. Secondary staining was per-
formed using anti-goat IgG FITC (Sigma-Aldrich, F7367)
at 1:200 dilution. Following treatment with the nuclear
stain—DAPI (Partec), stained iPSC colonies were photo-
graphed using a Bioscience Axiovert microscope (Axio-
cam, CarlZeiss) in combination with the associated
CarlZeiss software- AxioVision.
To assess the percentage of cells expressing the plur-
ipotent markers TRA-1-60 and SSEA-4, flow cytometric
analysis was performed, iPSC colonies were dissociated
using TrypLE™ Express (Thermo Fisher Scientific) for 5
min at 37 °C. Dissociated cells were stained with the fol-
lowing antibodies: anti-human TRA-1-60-FITC (Milli-
pore, FCMAB115) at 1:60 dilution and mouse anti-human
SSEA-4-PerCPCy™5.5 (BD, 561565) at 1:20. Cell popu-
lation was identified based on cell size and cell granularity.
Single cells were discriminated using Forward Scatter area
(FSC-A) and Forward Scatter Height (FSC-H) and live
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cells were gated from single cell population using DAPI
nuclear staining (Partec). The cells were acquired using
the BD LSRII flow cytometer (BD) and data analyzed
using FlowJo software (Tree Star, Ashland, OR, USA). At
least 10.000 events were collected for each analysis.
In vivo test of pluripotency
For in vivo analysis of pluripotency via teratoma for-
mation, 0.5× 106 iPSCs were resuspended in 50%
MatrigelTM (BD, 356234) and injected subcutaneously
into both flanks of adult SCID male mice. Two animals
were injected in each group. Following a period of
10 weeks, the mice were euthanized and the teratomae
were excised, processed and sectioned according to
standard procedures and stained for Weigert’s hematox-
ylin, Masson’s trichrome and Mayer’s hematoxylin and
Eosin histological analysis. Sections (5–8 µm) were
examined using bright field microscopy and stained tissue
photographed as appropriate.
Karyotyping and fingerprinting analysis
All cell lines were analyzed using Illumina CytoSNP
analysis and the BlueFuse Multi 4.3 software (Illumina,
San Diego, United States) according to standard protocols
of the manufacturer.
iPSC differentiation into hematopoietic progenitor cells
iPSCs maintained on Vitronectin™ in StemPro™ media
were cut in homogeneous pieces using a STEMPRO®
EZpassage™ tool (Thermo Fisher Scientific). Aggregates
were resuspended in Stemline® II (Sigma-Aldrich) differ-
entiation media supplemented with 1% penicillin/strepto-
mycin and cultured in ultra-low attachment culture plates at
37 °C and 5% CO2 in a humidified incubator for 3 days to
allow the formation of embryoid bodies (EBs). On day 3, EBs
were dissociated using TrypLE™ Express for 10min at 37 °C
and transferred to tissue-culture treated wells to allow cul-
ture under monolayer conditions at 37 °C and 5% CO2 in a
humidified incubator. Recombinant human BMP4 (day 0–2
10 ng/ml, day 2–16 20 ng/ml), VEGF (day 0–2 10 ng/ml, day
2–16 30 ng/ml), Wnt3A (10 ng/ml), GSK-3β Inhibitor VII (2
µM), Activin A (5 ng/ml), FGFα (10ng/ml), SCF (20 ng/ml),
IGF-2 (10 ng/ml), TPO (10 ng/ml), β-estradiol (0.4 ng/ml),
Heparin (5 µg/ml) and 3-isobutyl-1-methylxanthine (IBMX)
(50 µM) were added to the differentiation media as pre-
viously described18. All cytokines and compounds were
purchased from Peprotech except BMP4 and Wnt3A
(R&D), GSK-3β Inhibitor VII (Calbiochem) and β-estradiol,
Heparin and IBMX (Sigma-Aldrich).
Detection of mesodermal and hematopoietic markers by
flow cytometry
Differentiated cells were treated with 1X TrypLE™
Express for 5 min at 37 °C to obtain a single a cell
suspension. Cell pellets were resuspended in FACS buffer
(DPBS with FBS 2%) and cells were counted with a
hemocytometer. A final amount of 1× 105 cells resus-
pended in 100 µl of FACS buffer with a dilution of 1:20
antibody was used for each analysis. The following cell
surface antigens were analyzed for this study: KDR-PE
(BD, 560494), CD34-APC (BD, 555824), CD43-FITC
(Thermo Fisher Scientific, MHCD4301), CD41a-APCH7
(BD, 561422) and CD235a-BV421 (BD, 562938). Cells
were washed using the BD FACS Lyse/Wash assistant
(BD) and analyzed using BD LSRII flow cytometer (BD).
Size and cell complexity were used to identify cell popu-
lations in a scatter graph representation. Single cells were
discriminated using FSC-A and FSC-H and live cells were
gated from single cell population using DAPI nuclear
staining. Analysis of data was performed using FlowJo
software (Tree Star Inc.). At least 10.000 events were
collected for each analysis.
Analysis of hematopoietic potential of hematopoietic
progenitors by colony-forming unit assay
iPSC-derived hematopoietic progenitor cells were trea-
ted with 1X TrypLE™ Express for 5–10min at 37 °C to
obtain a single a cell suspension. TrypLE™ Express is
diluted in PBS and cells were pelleted by centrifugation at
300 g for 3 min. Cell pellets were resuspended in FACS
buffer (DPBS with 2% FBS) and cells were counted with a
hemocytometer. A final amount of 6× 104 cells resus-
pended in 300 µl of FACS buffer and mixed with 3ml of
Methocult™ methylcellulose media enriched with
recombinant cytokines (Stem Cell Technologies, 04435)
and 1.5 ml were plated in duplicate in 35-mm dishes.
Colonies were scored after 14 days of culture using light
microscope according to standard criteria and averaged
between the duplicate dishes.
RNA isolation and reverse transcription PCR (RT-PCR)
RNA from iPSCs and fibroblasts at day-7 of SeV
transduction used as positive Sendai control was extracted
using the ReliaPrepTM RNA Cell Miniprep System (Pro-
mega, Z6010) including DNase I treatment according to
the manufacturer’s instructions. cDNA was generated
from 1 µg of RNA using the GoScriptTM Reverse Tran-
scription System (Promega, A5000) according to the
manufacturer’s instructions.
For the PCR reaction mixture, 1 µl of cDNA produced
from 1 µg of RNA was amplified using 10 µM dNTP mix, 5X
Green GoTaq® Reaction Buffer and GoTaq® DNA Poly-
merase (5 u/µl) (Promega, M3175) and the following pri-
mers (10 µM) SeV-OCT4 forward: 5′-CCCGAAAGAGAA
AGCGAACCAG-3′;SeV-OCT4 reverse: 5′-AATGTATCGA
AGGTGCTCAA-3′; SeV-SOX2 forward: 5′-ATGCACCGC-
TACGACGTGAGCGC-3′; SeV-SOX2 reverse: 5′-AATG-
TATCGAAGGTGCTCAA-3′; SeV-Klf4 forward: 5′-TTCCT
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GCATGCCAGAGGAGCCC-3′; SeV-Klf4 reverse: 5′-AATG
TATCGAAGGTGCTCAA-3′; SeV-cMYC forward: 5′-TA
ACTGACTAGCAGGCTTGTCG-3′; SeV-cMYC reverse: 5′-
TCCACATACAGTCCTGGATGATGATG-3′; SeV for-
ward: 5′-GGATCACTAGGTGATATCGAGC-3′; SeV
reverse: 5′-ACCAGACAAGAGTTTAAGAGATATGTA
TC-3′. Oligonucleotides for the housekeeping gene-
GAPDH were used as a positive control of the amplification
reaction.
DNA isolation and quantitative PCR for telomere length
measurement
Genomic DNA was isolated using QiAamp DNA Mini
Kit (Qiagen) according to manufacturer’s instructions.
Telomere length was measured as abundance of telomeric
template versus a single copy gene (36B4) as previously
described62 using the following primers: TelA (5′-CGG
TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT
TGG GTT-3′); TelB (5′-GGC TTG CCT TAC CCT TAC
CCT TAC CCT TAC CCT TAC CCT-3′); 36B4F (5′-CAG
CAA GTG GGA AGG TGT AAT CC 3′) and 36B4R (5′-
CCC ATT CTA TCA TCA ACG GGT ACA A-3′). Three
internal control DNA samples of known telomere length
(10.4, 3.9 and 2 kb) were run within each plate to correct
for plate–to-plate variation. Measurements were per-
formed in triplicate. All PCRs were carried out on an
Applied Biosystems 7900HT Fast Real Time PCR system
with 384-well plate capacity. The intra-assay coefficient of
variation was 2.7% while the inter-assay coefficient of
variation was 5.1%.
Telomere repeat amplification analysis for telomerase
activity detection
Telomerase activity in iPSC and iPSC-derived hemato-
poietic progenitors was measured as previously descri-
bed63. Final amount of 100 ng was used from protein
lysate for each reaction. No protein/lysate samples were
used as negative controls and 100, 10, 1, and 0.1 ng of
protein lysate from Hela cells as positive controls.
Analysis of DNA damage, proliferation and apoptosis by
flow cytometry
Day 12 iPSC-derived hematopoietic progenitor cells
were exposed to 2M Hydroxyurea for 24 h and collected
at different time points (0, 1, 3, 8, and 24 h). DNA damage,
proliferation and apoptosis induction after HU-treatment
was analyzed using a flow cytometric kit according to
manufacturer’s instructions (BD). Briefly, at the specified
time points after HU treatment, the cells were labeled
with 50 µM BrdU and stained later with antibody anti-
human CD43-FITC. The labeled cells were then fixed,
permeabilised and labeled with anti-human γH2AX-Alexa
Fluor®647, anti-human BrdU- PerCPCy™5.5 and anti-
human Cleaved PARP (Asp214)-PE according to
manufacturer’s instructions. DNA content for cell cycle
analysis was determined by DAPI staining provided by the
kit. Size and cell complexity were used to identify cell
populations in a scatter graph representation and single
cells were discriminated using FSC area (FSC-A) and FSC
height (FSC-H). The cells were acquired using the BD
LSRII flow cytometer (BD) and data analyzed using
FlowJo software. At least 10.000 events were collected for
each analysis.
Exome sequencing analysis
DNA was extracted from 5 HLHS patient fibroblasts
using QIAamp DNA Micro kit (Qiagen, Germantown,
MD, 56304). Exome sequencing was performed by BGI.
Exome capture was performed using Agilent SureSelect
Human All Exon kit (V4). Libraries were constructed
following the Illumina Paired-End Sequencing Library
Preparation Protocol version 1.0.1 and then sequenced on
the Illumina GAIIx platform with version 4 chemistry and
version 4 flowcells. The sequencing reads were analyzed
using the following workflow to identify variants in
patient. The quality of sequencing reads was firstly
checked with FastQC (Version 0.11.2)64 Low quality bases
(Q< 20) on 3′ ends of reads were trimmed off using seqtk
(Version 1.0)65. Duplicated reads were then removed with
FastUniq (Version 1.1)66 before mapping to the human
reference genome GRCh37 with BWA (Version 0.7.6.a)67.
The alignments were refined with tools of the GATK suite
(Version 3.2)68. Variants were called according to GATK
Best Practice recommendations69,70, including recalibra-
tion. Freebayes (Version 1.0.1)71 was also used to call
variants from the same set of samples. The variants called
by Freebayes with total coverage ≥ 5, minor allele cover-
age ≥ 5 and variants call quality ≥ 20 were added to those
identified by GATK. Non-synonymous exonic variants
were subsequently filtered by quality and minor-allele
frequency (MAF) reported in the 1000 Genomes project
(2012 Feb release)72 and ESP650073. Variants with MAF
> 0.05 in either of the databases were excluded. ANNO-
VAR (Version 2014-07-22)74 was used for annotations
and prediction of functional consequences. Deleterious in
our study was defined by at least one of the predictors
[SIFT or PolyPHEN2] and those that had alternative allele
frequency less than 0.01 in both 1000 Genomes project
and ESP6500 (Supplementary Table 2).
Statistical analysis
Data are shown as mean± S.E.M. from at least three
independent experiments. The significance between
means was determined with Multiple t-test using Holm-
Sidak method and One-way ANOVA when Gaussian
distribution was assumed and with Kruskal-Wallis test
when Gaussian distribution was not assumed. Multiple
comparisons test for comparison between particular pairs
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of control and patient groups. Statistically significant
values were judged as follows: *P ≤ 0.05, **P ≤ 0.01, ***P ≤
0.001, ****P ≤ 0.0001. Statistical analysis was performed
using GraphPad Prism version 7.0 software and Minitab
17 statistical software.
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